First American Trust FSB Has $1.12 Million Position in Zoetis Inc. (NYSE:ZTS)

First American Trust FSB lessened its position in Zoetis Inc. (NYSE:ZTS) by 10.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,862 shares of the company’s stock after selling 822 shares during the period. First American Trust FSB’s holdings in Zoetis were worth $1,118,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Howard Capital Management Group LLC grew its stake in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after buying an additional 883 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Zoetis by 17.3% in the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after acquiring an additional 351,372 shares in the last quarter. Cerity Partners LLC grew its position in Zoetis by 29.0% during the 3rd quarter. Cerity Partners LLC now owns 152,822 shares of the company’s stock worth $29,859,000 after acquiring an additional 34,359 shares during the last quarter. Kingsview Wealth Management LLC increased its holdings in Zoetis by 8.5% during the 3rd quarter. Kingsview Wealth Management LLC now owns 9,889 shares of the company’s stock valued at $1,932,000 after purchasing an additional 775 shares in the last quarter. Finally, Algert Global LLC increased its holdings in Zoetis by 1,182.5% during the 3rd quarter. Algert Global LLC now owns 24,676 shares of the company’s stock valued at $4,821,000 after purchasing an additional 22,752 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ZTS. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Piper Sandler upped their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Finally, Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $215.90.

Zoetis Price Performance

ZTS opened at $163.22 on Tuesday. The company has a fifty day moving average price of $166.70 and a two-hundred day moving average price of $175.22. The firm has a market capitalization of $73.09 billion, a PE ratio of 29.84, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.